Equities

Mallinckrodt PLC

MCKPF:PKC

Mallinckrodt PLC

Actions
  • Price (USD)0.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 30 1899.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mallinckrodt plc develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies. The Company operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The Company focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.

  • Revenue in USD (TTM)1.91bn
  • Net income in USD-1.49bn
  • Incorporated2013
  • Employees2.80k
  • Location
    Mallinckrodt PLCCollege Business & Technology ParkCruiserath, BlanchardstownDUBLIN IrelandIRL
  • Phone+353 16960000
  • Websitehttps://www.mallinckrodt.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nexien Biopharma Inc0.00-246.18k1.38m0.00---------0.0038-0.00380.00-0.00480.00-------679.40-860.53---1,653.53-----------1.77--------42.22------
Agentix Corp0.00-1.01m1.42m-----------0.0253-0.02530.00-0.0710.00-------907.08-----------------96.41----------------
Lucy Scientific Discovery Inc16.73k-9.76m1.46m----17.96--87.14-6.34-7.210.01030.0460.0037--0.7276---215.45------49.97---58,360.55-----5.100.4615-------53.49------
Virpax Pharmaceuticals Inc0.00-16.89m1.48m7.00---------14.42-14.420.00-1.040.00----0.00-156.21-87.52-241.52-116.56--------------------29.84------
180 Life Sciences Corp0.00-16.24m1.53m4.00---------41.54-41.540.00-1.120.00----0.00-176.90-42.39-354.57-56.41-----------385.88--------48.52------
Bluejay Diagnostics Inc0.00-9.74m1.54m10.00--0.4232-----7.68-7.680.001.250.00----0.00-122.06---149.68--------------0.0048---100.00---7.07------
Finch Therapeutics Group Inc0.00-16.28m1.55m18.00--0.0816-----10.14-10.140.0011.860.00-------25.22---28.97--------------0.00---87.57--34.80------
InVitro International716.89k6.22k1.57m16.00197.342.15--2.190.00040.00040.04020.03211.15------0.9957.891.098.83----0.86765.90---------5.111.33-87.77-16.14----
Target Group Inc5.64m228.87k1.57m46.0019.62--1.480.2790.00010.00010.0088-0.01150.7648.60124.27115,104.103.10-37.99---78.7643.71--4.06-586.970.07360.01493.10----577.8392.84---58.54--
Mallinckrodt PLC1.91bn-1.49bn1.60m2.80k------0.0008-161.65-161.6389.6355.440.40621.574.94681,821.40-31.61-12.49-36.10-15.8526.2235.68-77.83-44.381.63-0.34560.6164---2.53-10.31-83.00------
Procyon Corp4.77m-387.79k1.62m17.00--0.764--0.3397-0.0478-0.04780.58910.27741.391.949.60280,817.70-10.813.52-13.694.2378.0173.30-7.782.522.22--0.00---3.223.1170.44--30.98--
Stemcell Holdings Inc9.98m3.10m1.64m------0.50080.16450.000080.000080.00030.00021.12--5.20--34.90--68.19--77.19--31.04------0.00--85.10--71.82------
Dermata Therapeutics Inc0.00-8.69m1.70m8.00--6.71-----24.67-24.670.000.57170.00----0.00-120.05---146.08--------------0.00------18.90------
Qualigen Therapeutics Inc0.00-12.48m1.70m4.00---------2.46-2.640.00-0.39230.00----0.00-118.15---364.72--21.30---------7.41--------10.22------
PainReform Ltd0.00-12.54m1.76m6.00--0.7109-----7.77-7.770.000.99880.00----0.00-158.88-55.47-222.89-68.20------------0.00-------6.28------
Hi-Great Group Holding Co109.49k-121.76k1.78m--------16.26-0.0012-0.00120.0011-0.00110.82240.8406-----91.46------46.50---111.21--0.0144-52.41-----47.32---3,789.70------
Data as of Dec 30 1899. Currency figures normalised to Mallinckrodt PLC's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.